Research programme: eye disorder protein therapeutics - Eleven Biotherapeutics

Drug Profile

Research programme: eye disorder protein therapeutics - Eleven Biotherapeutics

Alternative Names: EBI-006; EBI-018; EBI-028; EBI-029; EBI-031

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eleven Biotherapeutics
  • Class Proteins
  • Mechanism of Action Interleukin 1 receptor antagonists; Interleukin 17 receptor antagonists; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Uveitis
  • Research Age-related macular degeneration; Ocular inflammation

Most Recent Events

  • 13 Sep 2016 Eleven Biotherapeutics withdraws a phase I trial prior to enrolment for Diabetic macular oedema in USA (NCT02842541)
  • 07 Jul 2016 US FDA approves IND application for EBI 031 in Diabetic macular oedema and uveitis (9201624; 9199120)
  • 14 Jun 2016 EBI 031 licensed to Roche in world
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top